ArticleGynecologic oncology reports2022
The role of secondary full lymphadenectomy for patients with early-stage endometrial cancer and isolated tumor cells detected on sentinel lymph node biopsy.
Article in Gynecologic oncology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sentinel lymph node (SLN) mapping is a surgical technique with high accuracy in detecting metastases while limiting morbidity associated with full lymphadenectomy in endometrial cancer. Recent retrospective data suggests that recurrence risk is low for patients with isolated tumor cells (ITCs). The objective of this study was to describe the pathologic findings, postoperative complications, and outcomes of endometrial cancer patients with ITCs who subsequently underwent a second surgical procedure, full lymph node dissection (LND) following initial staging surgery. All patients with clinically early stage endometrial cancer who underwent planned minimally invasive surgical staging with SLN biopsy demonstrating ITCs at a single institution from 1/1/2017 to 12/31/2020 were identified retrospectively. Six patients with endometrial cancer with ITC who subsequently underwent secondary full LND were identified. Half of patients experienced postoperative complications within 30 days after LND, including persistent thigh numbness, a urinary tract infection, and a presyncopal episode. No patients had a change in stage as a result of subsequent full LND. One patient received no adjuvant therapy, while 83.3 % (5/6) received vaginal brachytherapy. One patient experienced distal recurrence six months after completing brachytherapy, while five remain without evidence of disease on most recent follow-up. In patients who underwent completion lymphadenectomy for ITCs identified during initial surgical staging for endometrial cancer, no additional lymph node metastatic disease was identified. This study supports current data there is a limited role for additional lymph node assessment in patients with early stage endometrial cancer with ITCs identified on SLN biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.